SPATS1

Across TCGA pan-cancer cohorts, SPATS1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPATS1 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SPATS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, LUAD, and UCS are the cancer types where SPATS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	III,IV	0.240	0.687	.003	13	view →
UCS	OS	Median	II,III,IV	0.007	0.616	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.442	.030	6	view →
SKCM	DFS	Median	All	0.192	0.640	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPATS1–KICH (DFS)

Open the KICH breakdown →